Mapi Pharma Ltd., a Ness Ziona, Israel-based development stage pharmaceutical company, received $10m in Series A financing.
The round was led by Shavit Capital with participation from chairman and CEO Mr. Ehud Marom.
The company intends to use the funds advance its lead product, the Glatiramer Acetate (GA) Depot, currently at Phase II, up to the initiation of the single pivotal Phase III needed for registration.
Led by Marom, Mapi Pharma is engaged in the development of The GA Depot, a once every four weeks injection for the treatment of multiple sclerosis.
FinSMEs
27/05/2015